ClinicalTrials.gov Identifier: NCT01399957
Mount Sinai Hospital
490 Blue Hills Ave
Hartford, CT 06112
has been approved by the FDA for improving walking speed in persons with
multiple sclerosis (MS). This observational
study was designed to capture information on additional possible benefits
person’s taking Ampyra may or may not experience. This project seeks to
determine factors that will predict a response (an increase in walking speed)
to dalfampridine. A
second goal is to identify possible additional benefits to taking Dalfampridine.
Status Closed to enrollment, in data analysis phase only.
Principal Investigators Albert Lo, MD, PhD, and Elizabeth Triche, PhD
Contact Kayla Olson, Study Coordinator
Phone (860) 714-2149